Trial Profile
Comparison of two new orally active anticoagulants dabigatran etexilate (Pradaxa) and apixaban (Eliquis) for thromboprophylaxis following hip and knee replacement surgery.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Feb 2018
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary)
- Indications Venous thromboembolism
- Focus Adverse reactions; Therapeutic Use
- 13 Feb 2018 New trial record